Endocrinol Metab.  2024 Apr;39(2):267-282. 10.3803/EnM.2024.1939.

Bone Loss after Solid Organ Transplantation: A Review of Organ-Specific Considerations

• Kim KJ
• Ha J
• Kim SW
• Kim JE
• Lee S
• Choi HS
• Hong N
• Kong SH
• Ahn SH
• Park SY
• Baek KH
• on Behalf of Metabolic Bone Disease Study Group of Korean Endocrine Society

• KMID: 2554631
• DOI: http://doi.org/10.3803/EnM.2024.1939

Abstract

This review article investigates solid organ transplantation-induced osteoporosis, a critical yet often overlooked issue, emphasizing its significance in post-transplant care. The initial sections provide a comprehensive understanding of the prevalence and multifactorial pathogenesis of transplantation osteoporosis, including factors such as deteriorating post-transplantation health, hormonal changes, and the impact of immunosuppressive medications. Furthermore, the review is dedicated to organ-specific considerations in transplantation osteoporosis, with separate analyses for kidney, liver, heart, and lung transplantations. Each section elucidates the unique challenges and management strategies pertinent to transplantation osteoporosis in relation to each organ type, highlighting the necessity of an organ-specific approach to fully understand the diverse manifestations and implications of transplantation osteoporosis. This review underscores the importance of this topic in transplant medicine, aiming to enhance awareness and knowledge among clinicians and researchers. By comprehensively examining transplantation osteoporosis, this study contributes to the development of improved management and care strategies, ultimately leading to improved patient outcomes in this vulnerable group. This detailed review serves as an essential resource for those involved in the complex multidisciplinary care of transplant recipients.

Keyword

Transplantation; Bone loss; Osteoporosis; Fractures; Bone mineral density

Figure

• 

  Fig. 1. Pathophysiology of transplantation-induced osteoporosis.

• 

  Fig. 2. Assessment and management of bone health in post-transplant patients: a summary. 25OHD, 25-hydroxyvitamin D; BMD, bone mineral density; PTH, parathyroid hormone; IV, intravenous.

Reference

1. Anastasilakis AD, Tsourdi E, Makras P, Polyzos SA, Meier C, McCloskey EV, et al. Bone disease following solid organ transplantation: a narrative review and recommendations for management from the European Calcified Tissue Society. Bone. 2019; 127:401–18.

2. Lan GB, Xie XB, Peng LK, Liu L, Song L, Dai HL. Current status of research on osteoporosis after solid organ transplantation: pathogenesis and management. Biomed Res Int. 2015; 2015:413169.

3. Black CK, Termanini KM, Aguirre O, Hawksworth JS, Sosin M. Solid organ transplantation in the 21st century. Ann Transl Med. 2018; 6:409.

4. Delmas PD. Osteoporosis in patients with organ transplants: a neglected problem. Lancet. 2001; 357:325–6.

5. Kulak CA, Cochenski Borba VZ, Kulak J, Ribeiro Custodio M. Osteoporosis after solid organ transplantation. Minerva Endocrinol. 2012; 37:221–31.

6. Kulak CA, Borba VZ, Kulak J Jr, Custodio MR. Osteoporosis after transplantation. Curr Osteoporos Rep. 2012; 10:48–55.

7. Maalouf NM, Shane E. Osteoporosis after solid organ transplantation. J Clin Endocrinol Metab. 2005; 90:2456–65.

8. Ebeling PR. Approach to the patient with transplantation-related bone loss. J Clin Endocrinol Metab. 2009; 94:1483–90.

9. Chen H, Lai YR, Yang Y, Gau SY, Huang CY, Tsai TH, et al. High risk of osteoporosis and fracture following solid organ transplantation: a population-based study. Front Endocrinol (Lausanne). 2023; 14:1167574.

10. Clifford J, Rosen MD. Primer on the metabolic bone diseases and disorders of mineral metabolism. 8th ed. Ames: Wiley-Blackwell; 2013. Chapter 61, Transplantation osteoporosis; p. 495-507.

11. Shane E, Epstein S. Transplantation osteoporosis. Transplant Rev. 2001; 15:11–32.

12. Kulak CA, Borba VZ, Kulak Junior J, Custodio MR. Bone disease after transplantation: osteoporosis and fractures risk. Arq Bras Endocrinol Metabol. 2014; 58:484–92.

13. Cohen A, Sambrook P, Shane E. Management of bone loss after organ transplantation. J Bone Miner Res. 2004; 19:1919–32.

14. Julian BA, Laskow DA, Dubovsky J, Dubovsky EV, Curtis JJ, Quarles LD. Rapid loss of vertebral mineral density after renal transplantation. N Engl J Med. 1991; 325:544–50.

15. Shane E, Papadopoulos A, Staron RB, Addesso V, Donovan D, McGregor C, et al. Bone loss and fracture after lung transplantation. Transplantation. 1999; 68:220–7.

16. Shane E, Rivas M, McMahon DJ, Staron RB, Silverberg SJ, Seibel MJ, et al. Bone loss and turnover after cardiac transplantation. J Clin Endocrinol Metab. 1997; 82:1497–506.

17. Floreani A, Mega A, Tizian L, Burra P, Boccagni P, Baldo V, et al. Bone metabolism and gonad function in male patients undergoing liver transplantation: a two-year longitudinal study. Osteoporos Int. 2001; 12:749–54.

18. Guo CY, Johnson A, Locke TJ, Eastell R. Mechanisms of bone loss after cardiac transplantation. Bone. 1998; 22:267–71.

19. Ramsey-Goldman R, Dunn JE, Dunlop DD, Stuart FP, Abecassis MM, Kaufman DB, et al. Increased risk of fracture in patients receiving solid organ transplants. J Bone Miner Res. 1999; 14:456–63.

20. Leidig-Bruckner G, Hosch S, Dodidou P, Ritschel D, Conradt C, Klose C, et al. Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study. Lancet. 2001; 357:342–7.

21. Compston JE. Osteoporosis after liver transplantation. Liver Transpl. 2003; 9:321–30.

22. Ninkovic M, Skingle SJ, Bearcroft PW, Bishop N, Alexander GJ, Compston JE. Incidence of vertebral fractures in the first three months after orthotopic liver transplantation. Eur J Gastroenterol Hepatol. 2000; 12:931–5.

23. Shane E, Rivas M, Staron RB, Silverberg SJ, Seibel MJ, Kuiper J, et al. Fracture after cardiac transplantation: a prospective longitudinal study. J Clin Endocrinol Metab. 1996; 81:1740–6.

24. Vautour LM, Melton LJ 3rd, Clarke BL, Achenbach SJ, Oberg AL, McCarthy JT. Long-term fracture risk following renal transplantation: a population-based study. Osteoporos Int. 2004; 15:160–7.

25. Ball AM, Gillen DL, Sherrard D, Weiss NS, Emerson SS, Seliger SL, et al. Risk of hip fracture among dialysis and renal transplant recipients. JAMA. 2002; 288:3014–8.

26. Kovvuru K, Kanduri SR, Vaitla P, Marathi R, Gosi S, Garcia Anton DF, et al. Risk factors and management of osteoporosis post-transplant. Medicina (Kaunas). 2020; 56:302.

27. Dienemann T, Ziolkowski SL, Bender S, Goral S, Long J, Baker JF, et al. Changes in body composition, muscle strength, and fat distribution following kidney transplantation. Am J Kidney Dis. 2021; 78:816–25.

28. Madersbacher S, Ludvik G, Stulnig T, Grunberger T, Maier U. The impact of liver transplantation on endocrine status in men. Clin Endocrinol (Oxf). 1996; 44:461–6.

29. Mass K, Quint EH, Punch MR, Merion RM. Gynecological and reproductive function after liver transplantation. Transplantation. 1996; 62:476–9.

30. Saha MT, Saha HH, Niskanen LK, Salmela KT, Pasternack AI. Time course of serum prolactin and sex hormones following successful renal transplantation. Nephron. 2002; 92:735–7.

31. Aris RM, Neuringer IP, Weiner MA, Egan TM, Ontjes D. Severe osteoporosis before and after lung transplantation. Chest. 1996; 109:1176–83.

32. Feller RB, McDonald JA, Sherbon KJ, McCaughan GW. Evidence of continuing bone recovery at a mean of 7 years after liver transplantation. Liver Transpl Surg. 1999; 5:407–13.

33. Julian BA, Quarles LD, Niemann KM. Musculoskeletal complications after renal transplantation: pathogenesis and treatment. Am J Kidney Dis. 1992; 19:99–120.

34. Bouquegneau A, Salam S, Delanaye P, Eastell R, Khwaja A. Bone disease after kidney transplantation. Clin J Am Soc Nephrol. 2016; 11:1282–96.

35. Epstein S. Post-transplantation bone disease: the role of immunosuppressive agents and the skeleton. J Bone Miner Res. 1996; 11:1–7.

36. Dolgos S, Hartmann A, Isaksen GA, Simonsen S, Bjortuft O, Boberg KM, et al. Osteoporosis is a prevalent finding in patients with solid organ failure awaiting transplantation: a population based study. Clin Transplant. 2010; 24:E145–52.

37. Yu TM, Lin CL, Chang SN, Sung FC, Huang ST, Kao CH. Osteoporosis and fractures after solid organ transplantation: a nationwide population-based cohort study. Mayo Clin Proc. 2014; 89:888–95.

38. Buckley L, Humphrey MB. Glucocorticoid-induced osteoporosis. N Engl J Med. 2018; 379:2547–56.

39. Adami G, Saag KG. Glucocorticoid-induced osteoporosis: 2019 concise clinical review. Osteoporos Int. 2019; 30:1145–56.

40. Rubin MR, Bilezikian JP. Clinical review 151: the role of parathyroid hormone in the pathogenesis of glucocorticoidinduced osteoporosis: a re-examination of the evidence. J Clin Endocrinol Metab. 2002; 87:4033–41.

41. Bonadonna S, Burattin A, Nuzzo M, Bugari G, Rosei EA, Valle D, et al. Chronic glucocorticoid treatment alters spontaneous pulsatile parathyroid hormone secretory dynamics in human subjects. Eur J Endocrinol. 2005; 152:199–205.

42. Klein GL. The effect of glucocorticoids on bone and muscle. Osteoporos Sarcopenia. 2015; 1:39–45.

43. Siekierka JJ, Sigal NH. FK-506 and cyclosporin A: immunosuppressive mechanism of action and beyond. Curr Opin Immunol. 1992; 4:548–52.

44. Orcel P, Bielakoff J, Modrowski D, Miravet L, de Vernejoul MC. Cyclosporin A induces in vivo inhibition of resorption and stimulation of formation in rat bone. J Bone Miner Res. 1989; 4:387–91.

45. McIntyre HD, Menzies B, Rigby R, Perry-Keene DA, Hawley CM, Hardie IR. Long-term bone loss after renal transplantation: comparison of immunosuppressive regimens. Clin Transplant. 1995; 9:20–4.

46. Stempfle HU, Werner C, Echtler S, Assum T, Meiser B, Angermann CE, et al. Rapid trabecular bone loss after cardiac transplantation using FK506 (tacrolimus)-based immunosuppression. Transplant Proc. 1998; 30:1132–3.

47. Monegal A, Navasa M, Guanabens N, Peris P, Pons F, Martinez de Osaba MJ, et al. Bone mass and mineral metabolism in liver transplant patients treated with FK506 or cyclosporine A. Calcif Tissue Int. 2001; 68:83–6.

48. Kanda J, Izumo N, Furukawa M, Shimakura T, Yamamoto N, Takahashi HE, et al. Effects of the calcineurin inhibitors cyclosporine and tacrolimus on bone metabolism in rats. Biomed Res. 2018; 39:131–9.

49. Movsowitz C, Epstein S, Fallon M, Ismail F, Thomas S. Cyclosporin-A in vivo produces severe osteopenia in the rat: effect of dose and duration of administration. Endocrinology. 1988; 123:2571–7.

50. Hardinger KL, Koch MJ, Brennan DC. Current and future immunosuppressive strategies in renal transplantation. Pharmacotherapy. 2004; 24:1159–76.

51. Mogi M, Kondo A. Down-regulation of mTOR leads to upregulation of osteoprotegerin in bone marrow cells. Biochem Biophys Res Commun. 2009; 384:82–6.

52. Kneissel M, Luong-Nguyen NH, Baptist M, Cortesi R, Zumstein-Mecker S, Kossida S, et al. Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts. Bone. 2004; 35:1144–56.

53. Gnant M, Baselga J, Rugo HS, Noguchi S, Burris HA, Piccart M, et al. Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2. J Natl Cancer Inst. 2013; 105:654–63.

54. Campistol JM, Holt DW, Epstein S, Gioud-Paquet M, Rutault K, Burke JT, et al. Bone metabolism in renal transplant patients treated with cyclosporine or sirolimus. Transpl Int. 2005; 18:1028–35.

55. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000; 47:85–118.

56. Trotter JL, Rodey GE, Gebel HM. Azathioprine decreases suppressor T cells in patients with multiple sclerosis. N Engl J Med. 1982; 306:365–6.

57. Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) guideline update: what’s changed and why it matters. Kidney Int. 2017; 92:26–36.

58. Pimentel A, Urena-Torres P, Zillikens MC, Bover J, CohenSolal M. Fractures in patients with CKD-diagnosis, treatment, and prevention: a review by members of the European Calcified Tissue Society and the European Renal Association of Nephrology Dialysis and Transplantation. Kidney Int. 2017; 92:1343–55.

59. Naylor KL, Li AH, Lam NN, Hodsman AB, Jamal SA, Garg AX. Fracture risk in kidney transplant recipients: a systematic review. Transplantation. 2013; 95:1461–70.

60. Durieux S, Mercadal L, Orcel P, Dao H, Rioux C, Bernard M, et al. Bone mineral density and fracture prevalence in long-term kidney graft recipients. Transplantation. 2002; 74:496–500.

61. Wilson LM, Rebholz CM, Jirru E, Liu MC, Zhang A, Gayleard J, et al. Benefits and harms of osteoporosis medications in patients with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2017; 166:649–58.

62. Jamal SA, Ljunggren O, Stehman-Breen C, Cummings SR, McClung MR, Goemaere S, et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Miner Res. 2011; 26:1829–35.

63. Whitlock RH, Leslie WD, Shaw J, Rigatto C, Thorlacius L, Komenda P, et al. The Fracture Risk Assessment Tool (FRAX®) predicts fracture risk in patients with chronic kidney disease. Kidney Int. 2019; 95:447–54.

64. Shevroja E, Lamy O, Hans D. Review on the utility of trabecular bone score, a surrogate of bone micro-architecture, in the chronic kidney disease spectrum and in kidney transplant recipients. Front Endocrinol (Lausanne). 2018; 9:561.

65. Evenepoel P, Cavalier E, D’Haese PC. Biomarkers predicting bone turnover in the setting of CKD. Curr Osteoporos Rep. 2017; 15:178–86.

66. Sprague SM, Bellorin-Font E, Jorgetti V, Carvalho AB, Malluche HH, Ferreira A, et al. Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis. Am J Kidney Dis. 2016; 67:559–66.

67. Evenepoel P, Behets GJ, Laurent MR, D’Haese PC. Update on the role of bone biopsy in the management of patients with CKD-MBD. J Nephrol. 2017; 30:645–52.

68. Vangala C, Pan J, Cotton RT, Ramanathan V. Mineral and bone disorders after kidney transplantation. Front Med (Lausanne). 2018; 5:211.

69. Segaud N, Legroux I, Hazzan M, Noel C, Cortet B. Changes in bone mineral density after kidney transplantation: 2-year assessment of a French cohort. Osteoporos Int. 2018; 29:1165–75.

70. Torregrosa JV, Ferreira AC, Cucchiari D, Ferreira A. Bone mineral disease after kidney transplantation. Calcif Tissue Int. 2021; 108:551–60.

71. Perez-Saez MJ, Herrera S, Prieto-Alhambra D, Nogues X, Vera M, Redondo-Pachon D, et al. Bone density, microarchitecture, and tissue quality long-term after kidney transplant. Transplantation. 2017; 101:1290–4.

72. Monier-Faugere MC, Mawad H, Qi Q, Friedler RM, Malluche HH. High prevalence of low bone turnover and occurrence of osteomalacia after kidney transplantation. J Am Soc Nephrol. 2000; 11:1093–9.

73. Versele EB, Van Laecke S, Dhondt AW, Verbeke F, Vanholder R, Van Biesen W, et al. Bisphosphonates for preventing bone disease in kidney transplant recipients: a meta-analysis of randomized controlled trials. Transpl Int. 2016; 29:153–64.

74. Nanmoku K, Shinzato T, Kubo T, Shimizu T, Yagisawa T. Effects of denosumab on hypercalcemia and bone mineral density loss in kidney transplant recipients. Clin Nephrol. 2019; 92:1–8.

75. Marques ID, Araujo MJ, Graciolli FG, Dos Reis LM, Pereira RM, Alvarenga JC, et al. A randomized trial of zoledronic acid to prevent bone loss in the first year after kidney transplantation. J Am Soc Nephrol. 2019; 30:355–65.

76. El-Agroudy AE, El-Husseini AA, El-Sayed M, Mohsen T, Ghoneim MA. A prospective randomized study for prevention of postrenal transplantation bone loss. Kidney Int. 2005; 67:2039–45.

77. Bonani M, Frey D, Brockmann J, Fehr T, Mueller TF, Saleh L, et al. Effect of twice-yearly denosumab on prevention of bone mineral density loss in de novo kidney transplant recipients: a randomized controlled trial. Am J Transplant. 2016; 16:1882–91.

78. Park W, Lee SH, Park KR, Rho SH, Chung WY, Kim HJ. Characteristics of bisphosphonate-related osteonecrosis of the jaw after kidney transplantation. J Craniofac Surg. 2012; 23:e510–4.

79. Rodriguez-Aguilar EF, Perez-Escobar J, Sanchez Herrera D, Garcia-Alanis M, Toapanta-Yanchapaxi L, GonzalezFlores E, et al. Bone disease and liver transplantation: a review. Transplant Proc. 2021; 53:2346–53.

80. Guichelaar MM, Kendall R, Malinchoc M, Hay JE. Bone mineral density before and after OLT: long-term follow-up and predictive factors. Liver Transpl. 2006; 12:1390–402.

81. Monegal A, Navasa M, Guanabens N, Peris P, Pons F, Martinez de Osaba MJ, et al. Bone disease after liver transplantation: a long-term prospective study of bone mass changes, hormonal status and histomorphometric characteristics. Osteoporos Int. 2001; 12:484–92.

82. Baccaro LF, Boin IF, Pedro AO, Costa-Paiva L, Leal AL, Ramos CD, et al. Decrease in bone mass in women after liver transplantation: associated factors. Transplant Proc. 2011; 43:1351–6.

83. Collier J. Bone disorders in chronic liver disease. Hepatology. 2007; 46:1271–8.

84. Guanabens N, Pares A. Liver and bone. Arch Biochem Biophys. 2010; 503:84–94.

85. van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford). 2000; 39:1383–9.

86. Han A, Park Y, Lee YK, Park SY, Park CY. Position statement: vitamin D intake to prevent osteoporosis and fracture in adults. J Bone Metab. 2022; 29:205–15.

87. Kim KM, Choi HS, Choi MJ, Chung HY. Calcium and vitamin D supplementations: 2015 position statement of the Korean Society for Bone and Mineral Research. J Bone Metab. 2015; 22:143–9.

88. Jeong HM, Kim DJ. Bone diseases in patients with chronic liver disease. Int J Mol Sci. 2019; 20:4270.

89. Atamaz F, Hepguler S, Akyildiz M, Karasu Z, Kilic M. Effects of alendronate on bone mineral density and bone metabolic markers in patients with liver transplantation. Osteoporos Int. 2006; 17:942–9.

90. Kaemmerer D, Schmidt B, Lehmann G, Wolf G, Hommann M, Settmacher U. Monthly ibandronate for the prevention of bone loss in patients after liver transplantation. Transplant Proc. 2012; 44:1362–7.

91. Misof BM, Bodingbauer M, Roschger P, Wekerle T, Pakrah B, Haas M, et al. Short-term effects of high-dose zoledronic acid treatment on bone mineralization density distribution after orthotopic liver transplantation. Calcif Tissue Int. 2008; 83:167–75.

92. Levy C, Harnois DM, Angulo P, Jorgensen R, Lindor KD. Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: results of a pilot study. Liver Int. 2005; 25:117–21.

93. Brunova J, Kratochvilova S, Stepankova J. Osteoporosis therapy with denosumab in organ transplant recipients. Front Endocrinol (Lausanne). 2018; 9:162.

94. Zavatta G, Vandi G, Di Dalmazi G, Repaci A, Ravaioli M, Cescon M, et al. Denosumab in post-liver transplantation osteoporosis: preliminary data on the effects on bone mineral density and turnover markers. Endocr Abstr. 2019; 63:GP110.

95. Stein E, Ebeling P, Shane E. Post-transplantation osteoporosis. Endocrinol Metab Clin North Am. 2007; 36:937–63.

96. Forien M, Coralli R, Verdonk C, Ottaviani S, Ebstein E, Demaria L, et al. Osteoporosis and risk of fracture in heart transplant patients. Front Endocrinol (Lausanne). 2023; 14:1252966.

97. Dalle Carbonare L, Zanatta M, Braga V, Sella S, Vilei MT, Feltrin G, et al. Densitometric threshold and vertebral fractures in heart transplant patients. Transplantation. 2011; 92:106–11.

98. Shane E, Mancini D, Aaronson K, Silverberg SJ, Seibel MJ, Addesso V, et al. Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med. 1997; 103:197–207.

99. Lofdahl E, Radegran G. Osteoporosis following heart transplantation and immunosuppressive therapy. Transplant Rev (Orlando). 2017; 31:232–9.

100. Schnoll-Sussman F, Katz PO. Clinical implications of emerging data on the safety of proton pump inhibitors. Curr Treat Options Gastroenterol. 2017; 15:1–9.

101. Stehlik J, Edwards LB, Kucheryavaya AY, Benden C, Christie JD, Dipchand AI, et al. The Registry of the International Society for Heart and Lung Transplantation: 29th official adult heart transplant report-2012. J Heart Lung Transplant. 2012; 31:1052–64.

102. Wang TK, O’Sullivan S, Gamble GD, Ruygrok PN. Bone density in heart or lung transplant recipients: a longitudinal study. Transplant Proc. 2013; 45:2357–65.

103. Van Cleemput J, Daenen W, Nijs J, Geusens P, Dequeker J, Vanhaecke J. Timing and quantification of bone loss in cardiac transplant recipients. Transpl Int. 1995; 8:196–200.

104. Costanzo MR, Dipchand A, Starling R, Anderson A, Chan M, Desai S, et al. The International Society of Heart and Lung Transplantation guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010; 29:914–56.

105. Kourek C, Karatzanos E, Nanas S, Karabinis A, Dimopoulos S. Exercise training in heart transplantation. World J Transplant. 2021; 11:466–79.

106. Cremer J, Struber M, Wagenbreth I, Nischelsky J, Demertzis S, Graeter T, et al. Progression of steroid-associated osteoporosis after heart transplantation. Ann Thorac Surg. 1999; 67:130–3.

107. Sambrook P, Henderson NK, Keogh A, MacDonald P, Glanville A, Spratt P, et al. Effect of calcitriol on bone loss after cardiac or lung transplantation. J Bone Miner Res. 2000; 15:1818–24.

108. Shane E, Addesso V, Namerow PB, McMahon DJ, Lo SH, Staron RB, et al. Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N Engl J Med. 2004; 350:767–76.

109. Fahrleitner-Pammer A, Piswanger-Soelkner JC, Pieber TR, Obermayer-Pietsch BM, Pilz S, Dimai HP, et al. Ibandronate prevents bone loss and reduces vertebral fracture risk in male cardiac transplant patients: a randomized doubleblind, placebo-controlled trial. J Bone Miner Res. 2009; 24:1335–44.

110. Shane E, Cohen A, Stein EM, McMahon DJ, Zhang C, Young P, et al. Zoledronic acid versus alendronate for the prevention of bone loss after heart or liver transplantation. J Clin Endocrinol Metab. 2012; 97:4481–90.

111. Uzquiano JC, Mendez AA, Bielsa AJ, Carmena MD, Jimenez JF, Sanz-Ayan P. Denosumab treatment for osteopenia or osteoporosis in heart transplant recipients: effects and safety. Transplant Rep. 2022; 7:100103.

112. Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017; 377:1417–27.

113. Fahrleitner-Pammer A, Wagner D, Krisper P, Amrein K, Dimai H. Teriparatide treatment in a heart transplant patient with a chronic kidney disease and a low-turnover bone disease: a case report. Osteoporos Int. 2017; 28:1149–52.

114. Vrieze A, de Greef MH, Wijkstra PJ, Wempe JB. Low bone mineral density in COPD patients related to worse lung function, low weight and decreased fat-free mass. Osteoporos Int. 2007; 18:1197–202.

115. Graat-Verboom L, Wouters EF, Smeenk FW, van den Borne BE, Lunde R, Spruit MA. Current status of research on osteoporosis in COPD: a systematic review. Eur Respir J. 2009; 34:209–18.

116. Maggi S, Siviero P, Gonnelli S, Schiraldi C, Malavolta N, Nuti R, et al. Osteoporosis risk in patients with chronic obstructive pulmonary disease: the EOLO study. J Clin Densitom. 2009; 12:345–52.

117. Ferrari SL, Nicod LP, Hamacher J, Spiliopoulos A, Slosman DO, Rochat T, et al. Osteoporosis in patients undergoing lung transplantation. Eur Respir J. 1996; 9:2378–82.

118. Hariman A, Alex C, Heroux A, Camacho P. Incidence of fractures after cardiac and lung transplantation: a single center experience. J Osteoporos. 2014; 2014:573041.

119. Caffarelli C, Tomai Pitinca MD, Alessandri M, Cameli P, Bargagli E, Bennett D, et al. Timing of osteoporotic vertebral fractures in lung and heart transplantation: a longitudinal study. J Clin Med. 2020; 9:2941.

120. Venado A, Kolaitis NA, Huang CY, Gao Y, Glidden DV, Soong A, et al. Frailty after lung transplantation is associated with impaired health-related quality of life and mortality. Thorax. 2020; 75:669–78.

121. Lyu DM, Zamora MR. Medical complications of lung transplantation. Proc Am Thorac Soc. 2009; 6:101–7.

122. Cahill BC, O’Rourke MK, Parker S, Stringham JC, Karwande SV, Knecht TP. Prevention of bone loss and fracture after lung transplantation: a pilot study. Transplantation. 2001; 72:1251–5.

123. Shane E, Papadopoulos A, Staron RB, Addesso V, Donovan D, McGregor C, et al. Bone loss and fracture after lung transplantation. Transplantation. 1999; 68:220–7.

124. Trombetti A, Gerbase MW, Spiliopoulos A, Slosman DO, Nicod LP, Rizzoli R. Bone mineral density in lung-transplant recipients before and after graft: prevention of lumbar spine post-transplantation-accelerated bone loss by pamidronate. J Heart Lung Transplant. 2000; 19:736–43.

125. Braith RW, Conner JA, Fulton MN, Lisor CF, Casey DP, Howe KS, et al. Comparison of alendronate vs alendronate plus mechanical loading as prophylaxis for osteoporosis in lung transplant recipients: a pilot study. J Heart Lung Transplant. 2007; 26:132–7.

126. Ng E, Topliss DJ, Paraskeva M, Paul E, Sztal-Mazer S. The utility of prophylactic zoledronic acid in patients undergoing lung transplantation. J Clin Densitom. 2021; 24:581–90.

127. Shrosbree JE, Elder GJ, Eisman JA, Center JR. Acute hypocalcaemia following denosumab in heart and lung transplant patients with osteoporosis. Intern Med J. 2018; 48:681–7.